» Articles » PMID: 6406907

Characterization of Rat Hypothalamic Growth Hormone-releasing Factor

Overview
Journal Nature
Specialty Science
Date 1983 Jun 9
PMID 6406907
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

The importance of the hypothalamus in the regulation of growth hormone (GH) secretion from the adenohypophysis has been supported by experimental and clinical evidence. It has been observed that GH secretion is in part controlled by hypothalamic GH release-inhibiting factors, two forms of which, somatostatin-14 (ref. 5) and somatostatin-28 (refs 6-9), have been characterized. Peptides with GH-releasing activity were recently purified from two human pancreatic tumours of acromegalic patients and characterized. Synthetic versions of these human pancreatic tumour GH-releasing factors (hpGRFs) were found to be potent GH secretagogues in vitro and in vivo and to exhibit actions and interactions similar to those observed with partially purified hypothalamic GRF. GH-releasing peptides have been purified from hypothalami of various species but the structure of natural hypothalamic GRF has not yet been reported. We now describe the purification, sequence analysis and synthesis of a 43-residue polypeptide isolated from rat hypothalamic extracts on the basis of its ability to stimulate GH secretion from cultured rat adenohypophyseal cells. The native polypeptide and its synthetic replicate do not differ significantly in their biological potencies and intrinsic activities. We propose that this polypeptide, which shows 67% homology with the corresponding N-terminal 43 residues in hpGRF-44, is the long-sought rat hypothalamic GRF (rhGRF).

Citing Articles

Effects of GH/IGF axis on bone and cartilage.

Dixit M, Poudel S, Yakar S Mol Cell Endocrinol. 2020; 519:111052.

PMID: 33068640 PMC: 7736189. DOI: 10.1016/j.mce.2020.111052.


Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness.

Hokfelt T, Barde S, Xu Z, Kuteeva E, Ruegg J, Le Maitre E Front Neural Circuits. 2019; 12:106.

PMID: 30627087 PMC: 6309708. DOI: 10.3389/fncir.2018.00106.


Acromegaly and Cushing's syndrome caused by a neuroendocrine tumor arising within a sacrococcygeal teratoma.

Babiker T, Kyrodimou E, Berney D, Gurnell M, Drake W, Brooke A Clin Case Rep. 2017; 5(11):1768-1771.

PMID: 29152267 PMC: 5676263. DOI: 10.1002/ccr3.1148.


Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Lindsey R, Mohan S Mol Cell Endocrinol. 2015; 432:44-55.

PMID: 26408965 PMC: 4808510. DOI: 10.1016/j.mce.2015.09.017.


Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Lee H, Kim S, Oh Y, Cho S, Schleimer R, Lee Y Am J Respir Cell Mol Biol. 2013; 50(4):667-77.

PMID: 24219511 PMC: 5455301. DOI: 10.1165/rcmb.2013-0397TR.